Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1175 of 2051 entries
View as:

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

Phase: N/A Priority: Normal
NCT ID: NCT04938817 Org: User:
Start: 08/19/21 End: 12/10/29 Due: 12/10/30

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Phase: N/A Priority: Normal
NCT ID: NCT04305041 Org: User:
Start: 06/26/20 End: 04/03/30 Due: 04/03/31

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Phase: N/A Priority: Normal
NCT ID: NCT04165798 Org: User:
Start: 12/19/19 End: 02/13/32 Due: 02/13/33

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Phase: N/A Priority: Normal
NCT ID: NCT04165070 Org: User:
Start: 12/19/19 End: 02/13/32 Due: 02/13/33

A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)

Phase: N/A Priority: Normal
NCT ID: NCT03217565 Org: User:
Start: 02/06/19 End: 04/06/23 Due: 04/06/24

Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

Phase: N/A Priority: Normal
NCT ID: NCT00139932 Org: User:
Start: 09/01/05 End: 11/21/06 Due: 11/21/07

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00575380 Org: User:
Start: 12/31/07 End: - Due: -

A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)

Phase: N/A Priority: Normal
NCT ID: NCT06880874 Org: User:
Start: 04/02/25 End: 05/31/25 Due: 05/31/26

Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)

Phase: N/A Priority: Normal
NCT ID: NCT00389987 Org: User:
Start: 09/30/01 End: 05/31/04 Due: 05/31/05

A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002)

Phase: N/A Priority: Normal
NCT ID: NCT00770341 Org: User:
Start: 09/30/08 End: 02/28/10 Due: 02/28/11

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Phase: N/A Priority: Normal
NCT ID: NCT04934722 Org: User:
Start: 05/25/21 End: 09/30/25 Due: 09/30/26

Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)

Phase: N/A Priority: Normal
NCT ID: NCT00632203 Org: User:
Start: 03/04/08 End: 01/07/11 Due: 01/07/12

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Phase: N/A Priority: Normal
NCT ID: NCT01798849 Org: User:
Start: 03/15/13 End: 07/17/13 Due: 07/17/14

A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00770159 Org: User:
Start: 11/30/04 End: 11/30/05 Due: 11/30/06

A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)

Phase: N/A Priority: Normal
NCT ID: NCT06294912 Org: User:
Start: 04/18/24 End: 01/06/25 Due: 01/06/26

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

Phase: N/A Priority: Normal
NCT ID: NCT05769595 Org: User:
Start: 06/14/23 End: 02/15/24 Due: 02/15/25

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Phase: N/A Priority: Normal
NCT ID: NCT05696080 Org: User:
Start: 02/13/23 End: 02/16/24 Due: 02/16/25

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Phase: N/A Priority: Normal
NCT ID: NCT06783192 Org: User:
Start: 08/14/23 End: 10/11/23 Due: 10/11/24

Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00684567 Org: User:
Start: 09/27/05 End: 10/31/07 Due: 10/31/08

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Phase: N/A Priority: Normal
NCT ID: NCT00500006 Org: User:
Start: 10/31/07 End: 11/30/07 Due: 11/30/08

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Phase: N/A Priority: Normal
NCT ID: NCT00106145 Org: User:
Start: 04/30/05 End: 08/31/11 Due: 08/31/12

A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00789321 Org: User:
Start: 07/31/08 End: 03/31/09 Due: 03/31/10

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Phase: N/A Priority: Normal
NCT ID: NCT02332668 Org: User:
Start: 03/18/15 End: 10/25/27 Due: 10/25/28

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Phase: N/A Priority: Normal
NCT ID: NCT04303169 Org: User:
Start: 06/26/20 End: 04/03/30 Due: 04/03/31

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

Phase: N/A Priority: Normal
NCT ID: NCT04738487 Org: User:
Start: 04/07/21 End: 12/31/25 Due: 12/31/26